Full Text View
Tabular View
No Study Results Posted
Related Studies
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis
This study has been terminated.
Study NCT00832208   Information provided by Drugs for Neglected Diseases

First Received on January 29, 2009.   Last Updated on March 9, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Visceral Leishmaniasis
Additional conditions recognized in this trial
Leishmaniasis
Leishmaniasis, Visceral
More general conditions related to this trial
Euglenozoa Infections
Parasitic Diseases
Protozoan Infections
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Interventions listed in this trial
Liposomal amphotericin B (Ambisome)
Additional drug interventions recognized in this trial
Amphotericin B
Liposomal amphotericin B
More general drug interventions related to this trial
Amebicides
Anti-Bacterial Agents
Anti-Infective Agents
Antifungal Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Drugs for Neglected Diseases
Addis Ababa University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services